Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
The Effectiveness of Cyclosporine Versus Methotrexate in the Treatment of Pediatric Alopecia Areata in Routine Clinical Care: a Patient Preference Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 4
- Sponsor
- Erasmus Medical Center
- Participants (registry)
- 50
- Start
- November 2025
- Primary completion
- November 2027 (planned)
- Study completion
- November 2027 (planned)
- Last registry update
- February 2026
- Countries
- Netherlands
Conditions studied: Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU), Alopecia Totalis (AT), Alopecia Areata (& Ophiasis)
Interventions: Methotrexate, Cyclosporin (CSA)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.